Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vectura, Unilever Establish Specialty Pharmaceutical Company

This article was originally published in The Pink Sheet Daily

Executive Summary

PharmaKodex will apply novel oral and dermal delivery mechanisms to existing therapies.

You may also be interested in...



Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.

Novartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications

New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal

Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.

Topics

UsernamePublicRestriction

Register

LL033172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel